86 related articles for article (PubMed ID: 27077749)
1. Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma.
Grau JJ; Mesía R; de la Iglesia-Vicente M; Williams ES; Taberna M; Caballero M; Larque AB; de la Oliva J; Cordón-Cardo C; Domingo-Domenech J
Oncology; 2016; 90(5):267-72. PubMed ID: 27077749
[TBL] [Abstract][Full Text] [Related]
2. Detection of putative stem cell markers, CD44/CD133, in primary and lymph node metastases in head and neck squamous cell carcinomas. A preliminary immunohistochemical and in vitro study.
Mannelli G; Magnelli L; Deganello A; Busoni M; Meccariello G; Parrinello G; Gallo O
Clin Otolaryngol; 2015 Aug; 40(4):312-20. PubMed ID: 25641707
[TBL] [Abstract][Full Text] [Related]
3. Spatial distribution of cancer stem cells in head and neck squamous cell carcinomas.
Hildebrand LC; Carvalho AL; Lauxen IS; Nör JE; Cerski CT; Sant'Ana Filho M
J Oral Pathol Med; 2014 Aug; 43(7):499-506. PubMed ID: 24527751
[TBL] [Abstract][Full Text] [Related]
4. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness.
Joshua B; Kaplan MJ; Doweck I; Pai R; Weissman IL; Prince ME; Ailles LE
Head Neck; 2012 Jan; 34(1):42-9. PubMed ID: 21322081
[TBL] [Abstract][Full Text] [Related]
5. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
7. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.
Pavón MA; Parreño M; León X; Sancho FJ; Céspedes MV; Casanova I; Lopez-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Int J Cancer; 2008 Sep; 123(5):1068-79. PubMed ID: 18546291
[TBL] [Abstract][Full Text] [Related]
8. A basal-cell-like compartment in head and neck squamous cell carcinomas represents the invasive front of the tumor and is expressing MMP-9.
Sterz CM; Kulle C; Dakic B; Makarova G; Böttcher MC; Bette M; Werner JA; Mandic R
Oral Oncol; 2010 Feb; 46(2):116-22. PubMed ID: 20036607
[TBL] [Abstract][Full Text] [Related]
9. The effects of CD44 down-regulation on stem cell properties of head and neck cancer cell lines.
Kidwai F; Costea DE; Hutchison I; Mackenzie I
J Oral Pathol Med; 2013 Oct; 42(9):682-90. PubMed ID: 23627635
[TBL] [Abstract][Full Text] [Related]
10. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Terada A; Hyodo I; Ogawa T; Fukushima M
Oncology; 2007; 73(1-2):104-11. PubMed ID: 18337622
[TBL] [Abstract][Full Text] [Related]
11. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
12. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC; Kang HJ; Moon JH
Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome.
de Koning PJ; Bovenschen N; Leusink FK; Broekhuizen R; Quadir R; van Gemert JT; Hordijk GJ; Chang WS; van der Tweel I; Tilanus MG; Kummer JA
Int J Cancer; 2009 Oct; 125(7):1542-50. PubMed ID: 19569240
[TBL] [Abstract][Full Text] [Related]
14. Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis.
Sun S; Wang Z
Int J Cancer; 2011 Nov; 129(10):2337-48. PubMed ID: 21225626
[TBL] [Abstract][Full Text] [Related]
15. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma.
Kokko LL; Hurme S; Maula SM; Alanen K; Grénman R; Kinnunen I; Ventelä S
Oral Oncol; 2011 Jun; 47(6):510-6. PubMed ID: 21514878
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer.
Wang SJ; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2006 Jul; 132(7):771-8. PubMed ID: 16847188
[TBL] [Abstract][Full Text] [Related]
17. Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer.
Aso T; Matsuo M; Kiyohara H; Taguchi K; Rikimaru F; Shimokawa M; Segawa Y; Higaki Y; Umeno H; Nakashima T; Masuda M
PLoS One; 2015; 10(3):e0116596. PubMed ID: 25751671
[TBL] [Abstract][Full Text] [Related]
18. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
[TBL] [Abstract][Full Text] [Related]
19. Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer.
Pries R; Witrkopf N; Trenkle T; Nitsch SM; Wollenberg B
In Vivo; 2008; 22(1):89-92. PubMed ID: 18396788
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma.
Gröbe A; Eichhorn W; Fraederich M; Kluwe L; Vashist Y; Wikner J; Smeets R; Simon R; Sauter G; Heiland M; Blessmann M
J Oral Pathol Med; 2014 Mar; 43(3):205-10. PubMed ID: 24020871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
